Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The combination of calcipotriol and betamethasone dipropionate used in an ointment
formulation (Daivobet® ointment) has shown to have an excellent efficacy and safety in the
short-term and long-term management of psoriasis vulgaris. A newly developed gel formulation
(Xamiol® gel) of calcipotriol and betamethasone dipropionate has recently been approved and
marketed in Korea as a topical treatment of moderate to severe scalp psoriasis and non-scalp
psoriasis vulgaris.
Xamiol® gel, the investigational product (IP) used in this study, prevents keratinization by
normalizing the reproduction cycle of skin cells. It also relieves itching associated with
psoriasis. Xamiol® gel was initially approved for treatment of moderate to severe scalp
psoriasis and its label was extended to non-scalp psoriasis vulgaris in October 2012.
Since patient compliance is one of the important factors in achieving effective outcomes in
the treatment of psoriasis, the once daily dosing of Xamiol® gel is expected to enhance
compliance and treatment outcomes as well as to provide a safe and effective therapeutic
option.